MTOR inhibitors: Changing landscape of endocrine-resistant breast cancer

Saranya Chumsri, Gauri Sabnis, Katherine Tkaczuk, Angela Brodie

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Most breast cancer (BC) patients have tumors that express hormone receptors (HRs). Although endocrine therapy, such as aromatase inhibitors, is very effective, most patients with metastatic HR-positive (HR+) BC become resistant to endocrine therapy at some point in their treatment and subsequently require chemotherapy. The PI3K/mTOR pathway is often upregulated in endocrine-resistant BC patients and, therefore, has been one of the targets for development of new agents. Recently, a Phase III trial (BOLERO-2) in aromatase inhibitor-resistant BC patients showed a significant improvement in time to progression with the combination of everolimus and exemestane compared with exemestane alone, confirming the importance of the PI3K/mTOR pathway in endocrine-resistant BC. Side effects from mTOR inhibitors are manageable, but early detection and proactive management are required to ensure patients' safety, compliance and continuity of treatment. Thus, mTOR inhibitors offer a new hope and promise for patients with HR+ BC.

Original languageEnglish (US)
Pages (from-to)443-456
Number of pages14
JournalFuture Oncology
Volume10
Issue number3
DOIs
StatePublished - Feb 2014
Externally publishedYes

Fingerprint

exemestane
Breast Neoplasms
Hormones
Aromatase Inhibitors
Phosphatidylinositol 3-Kinases
Hope
Therapeutics
Patient Safety
Patient Compliance
Drug Therapy
Neoplasms

Keywords

  • Aromatase inhibitor
  • Breast cancer
  • Endocrine resistance
  • Hormone receptor
  • mTOR inhibitor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

MTOR inhibitors : Changing landscape of endocrine-resistant breast cancer. / Chumsri, Saranya; Sabnis, Gauri; Tkaczuk, Katherine; Brodie, Angela.

In: Future Oncology, Vol. 10, No. 3, 02.2014, p. 443-456.

Research output: Contribution to journalReview article

Chumsri, Saranya ; Sabnis, Gauri ; Tkaczuk, Katherine ; Brodie, Angela. / MTOR inhibitors : Changing landscape of endocrine-resistant breast cancer. In: Future Oncology. 2014 ; Vol. 10, No. 3. pp. 443-456.
@article{e9b829bd576c4bd5923252c2be9bd9ca,
title = "MTOR inhibitors: Changing landscape of endocrine-resistant breast cancer",
abstract = "Most breast cancer (BC) patients have tumors that express hormone receptors (HRs). Although endocrine therapy, such as aromatase inhibitors, is very effective, most patients with metastatic HR-positive (HR+) BC become resistant to endocrine therapy at some point in their treatment and subsequently require chemotherapy. The PI3K/mTOR pathway is often upregulated in endocrine-resistant BC patients and, therefore, has been one of the targets for development of new agents. Recently, a Phase III trial (BOLERO-2) in aromatase inhibitor-resistant BC patients showed a significant improvement in time to progression with the combination of everolimus and exemestane compared with exemestane alone, confirming the importance of the PI3K/mTOR pathway in endocrine-resistant BC. Side effects from mTOR inhibitors are manageable, but early detection and proactive management are required to ensure patients' safety, compliance and continuity of treatment. Thus, mTOR inhibitors offer a new hope and promise for patients with HR+ BC.",
keywords = "Aromatase inhibitor, Breast cancer, Endocrine resistance, Hormone receptor, mTOR inhibitor",
author = "Saranya Chumsri and Gauri Sabnis and Katherine Tkaczuk and Angela Brodie",
year = "2014",
month = "2",
doi = "10.2217/fon.13.178",
language = "English (US)",
volume = "10",
pages = "443--456",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - MTOR inhibitors

T2 - Changing landscape of endocrine-resistant breast cancer

AU - Chumsri, Saranya

AU - Sabnis, Gauri

AU - Tkaczuk, Katherine

AU - Brodie, Angela

PY - 2014/2

Y1 - 2014/2

N2 - Most breast cancer (BC) patients have tumors that express hormone receptors (HRs). Although endocrine therapy, such as aromatase inhibitors, is very effective, most patients with metastatic HR-positive (HR+) BC become resistant to endocrine therapy at some point in their treatment and subsequently require chemotherapy. The PI3K/mTOR pathway is often upregulated in endocrine-resistant BC patients and, therefore, has been one of the targets for development of new agents. Recently, a Phase III trial (BOLERO-2) in aromatase inhibitor-resistant BC patients showed a significant improvement in time to progression with the combination of everolimus and exemestane compared with exemestane alone, confirming the importance of the PI3K/mTOR pathway in endocrine-resistant BC. Side effects from mTOR inhibitors are manageable, but early detection and proactive management are required to ensure patients' safety, compliance and continuity of treatment. Thus, mTOR inhibitors offer a new hope and promise for patients with HR+ BC.

AB - Most breast cancer (BC) patients have tumors that express hormone receptors (HRs). Although endocrine therapy, such as aromatase inhibitors, is very effective, most patients with metastatic HR-positive (HR+) BC become resistant to endocrine therapy at some point in their treatment and subsequently require chemotherapy. The PI3K/mTOR pathway is often upregulated in endocrine-resistant BC patients and, therefore, has been one of the targets for development of new agents. Recently, a Phase III trial (BOLERO-2) in aromatase inhibitor-resistant BC patients showed a significant improvement in time to progression with the combination of everolimus and exemestane compared with exemestane alone, confirming the importance of the PI3K/mTOR pathway in endocrine-resistant BC. Side effects from mTOR inhibitors are manageable, but early detection and proactive management are required to ensure patients' safety, compliance and continuity of treatment. Thus, mTOR inhibitors offer a new hope and promise for patients with HR+ BC.

KW - Aromatase inhibitor

KW - Breast cancer

KW - Endocrine resistance

KW - Hormone receptor

KW - mTOR inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84896815337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896815337&partnerID=8YFLogxK

U2 - 10.2217/fon.13.178

DO - 10.2217/fon.13.178

M3 - Review article

C2 - 24559450

AN - SCOPUS:84896815337

VL - 10

SP - 443

EP - 456

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 3

ER -